---
title: "Diabetes Management Guidelines"
tags: [guidelines, diabetes, endocrinology]
sidebar: ccms_guidelines_sidebar
permalink: /guidelines/diabetes-management-guidelines.html
summary: Comprehensive guidelines for diabetes mellitus management
---

# Diabetes Management Guidelines

Evidence-based guidelines for the comprehensive management of diabetes mellitus across all types and stages.

## Diagnosis and Classification

### Diagnostic Criteria
- **Fasting Plasma Glucose**: ≥126 mg/dL (7.0 mmol/L)
- **2-hour OGTT**: ≥200 mg/dL (11.1 mmol/L)
- **Random Plasma Glucose**: ≥200 mg/dL with symptoms
- **HbA1c**: ≥6.5% (48 mmol/mol)

### Classification
- **Type 1 Diabetes**: Autoimmune beta-cell destruction
- **Type 2 Diabetes**: Insulin resistance and relative insulin deficiency
- **Gestational Diabetes**: Diabetes diagnosed during pregnancy
- **Other Specific Types**: MODY, drug-induced, pancreatic disease

## Glycemic Targets

### General Population
- **HbA1c**: <7% (53 mmol/mol) for most adults
- **Preprandial Glucose**: 80-130 mg/dL (4.4-7.2 mmol/L)
- **Postprandial Glucose**: <180 mg/dL (10.0 mmol/L)

### Individualized Targets
- **Tight Control**: <6.5% for newly diagnosed, long life expectancy
- **Less Stringent**: <8% for history of severe hypoglycemia, limited life expectancy
- **Pregnancy**: <6% if possible without hypoglycemia

## Pharmacological Management

### First-Line Therapy
- **Metformin**: 500-2000mg daily, unless contraindicated
- **Lifestyle Modification**: Diet, exercise, weight management

### Second-Line Options
- **Sulfonylureas**: Glipizide, glimepiride
- **DPP-4 Inhibitors**: Sitagliptin, linagliptin
- **GLP-1 Receptor Agonists**: Liraglutide, semaglutide
- **SGLT2 Inhibitors**: Empagliflozin, dapagliflozin

### Insulin Therapy
- **Basal Insulin**: Glargine, detemir, degludec
- **Prandial Insulin**: Lispro, aspart, glulisine
- **Premixed Insulin**: 70/30, 75/25 combinations

## Monitoring and Complications

### Regular Monitoring
- **HbA1c**: Every 3 months if not at target, every 6 months if stable
- **Self-Monitoring**: Frequency based on treatment regimen
- **Continuous Glucose Monitoring**: For patients with frequent hypoglycemia

### Complication Screening
- **Retinopathy**: Annual dilated eye exam
- **Nephropathy**: Annual microalbuminuria, eGFR monitoring
- **Neuropathy**: Annual foot exam, monofilament testing
- **Cardiovascular**: Annual lipid panel, blood pressure monitoring

## Special Populations

### Pregnancy
- **Preconception**: HbA1c <6.5% if possible
- **Gestational Diabetes**: Fasting <95 mg/dL, 1-hour <140 mg/dL
- **Insulin**: Preferred during pregnancy

### Elderly Patients
- **Frailty Assessment**: Individualized glycemic targets
- **Hypoglycemia Risk**: Avoid sulfonylureas in frail elderly
- **Cognitive Function**: Regular assessment

## References
- American Diabetes Association Standards of Care
- International Diabetes Federation Guidelines
- Endocrine Society Clinical Practice Guidelines
